Antineoplastic Combinations

Kisqali Femara Co-Pack (letrozole/ribociclib)

KISQALI® (ribociclib) is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

 

 

 

Manufacturer's Website: Kisqali                                                                                                                                           Average retail cost: $2,800/month

Lonsurf (tipiracil/trifluridine)

Trifluridine/tipiracil (trade name Lonsurf) is a combination drug for the treatment of metastatic colorectal cancer. It is a combination of two active pharmaceutical ingredients: trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor. Tipiracil prevents rapid metabolism of trifluridine, increasing the bioavailability of trifluridine...Wikipedia

 

 

 

Manufacturer's Website: Lonsurf                                                                                                                                          Average retail cost: $12,150/month

Vyxeos (cytarabine liposomal/daunorubicin liposomal)

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

 

 

Manufacturer's Website: Vyxeos                                                                                                                                        Average retail cost: *

 

* This prescription is provided by your healthcare provider. It cannot be filled in a pharmacy and may be expensive.

Copyright 2006-2020 Automated Clinical Guidelines, LLC. All rights reserved.